Sathar Aslam, Dhai Amaboo, van der Linde Stephan
Dev World Bioeth. 2014 Dec;14(3):150-7. doi: 10.1111/dewb.12018. Epub 2013 May 31.
Human Biological Materials (HBMs) are an invaluable resource in biomedical research.
To determine if researchers and a Research Ethics Committee (REC) at a South African institution addressed ethical issues pertaining to HBMs in collaborative research with developed countries.
Ethically approved retrospective cross-sectional descriptive audit.
Of the 1305 protocols audited, 151 (11.57%) fulfilled the study's inclusion criteria. Compared to other developed countries, a majority of sponsors (90) were from the USA (p = 0.0001). The principle investigators (PIs) in all 151 protocols informed the REC of their intent to store HBMs. Only 132 protocols informed research participants (P < 0.0001). In 148 protocols informed consent (IC) was obtained from research participants, 116 protocols (76.8%) solicited broad consent compared to specific consent (32; 21.2%) [p < 0.0001]. In 105 cases a code was used to maintain confidentiality. HBMs were anonymised in 14 protocols [p < 0.0001]. More protocols informed the REC (90) than the research participants (67) that HBMs would be exported (p = 0.011). Export permits (EPs) and Material Transfer Agreements (MTAs) were not available in 109 and 143 protocols, respectively.
Researchers and the REC did not adequately address the inter-related ethical and regulatory issues pertaining to HBMs. There was a lack of congruence between the ethical guidelines of developed countries and their actions which are central to the access to HBMs in collaborative research. HBMs may be leaving South Africa without EPs and MTAs during the process of international collaborative research.
人类生物材料(HBMs)是生物医学研究中宝贵的资源。
确定南非一家机构的研究人员和研究伦理委员会(REC)在与发达国家的合作研究中是否处理了与人类生物材料相关的伦理问题。
经伦理批准的回顾性横断面描述性审计。
在审计的1305份方案中,151份(11.57%)符合研究纳入标准。与其他发达国家相比,大多数资助者(90个)来自美国(p = 0.0001)。所有151份方案中的主要研究者(PIs)告知伦理委员会他们储存人类生物材料的意图。只有132份方案告知了研究参与者(P < 0.0001)。在148份方案中获得了研究参与者的知情同意(IC),116份方案(76.8%)征求了广泛同意,而特定同意为32份(21.2%)[p < 0.0001]。在105个案例中使用了代码来维护保密性。14份方案中人类生物材料进行了匿名化处理[p < 0.0001]。告知伦理委员会(90份)人类生物材料将被出口的方案比告知研究参与者(67份)的更多(p = 0.011)。分别有109份和143份方案没有出口许可证(EPs)和材料转让协议(MTAs)。
研究人员和伦理委员会没有充分处理与人类生物材料相关的相互关联的伦理和监管问题。发达国家的伦理准则与其行动之间缺乏一致性,而这些行动对于合作研究中获取人类生物材料至关重要。在国际合作研究过程中,人类生物材料可能在没有出口许可证和材料转让协议的情况下离开南非。